Article
Functional characterization of novel mutations affecting survivin (BIRC5)-mediated therapy resistance in head and neck cancer patients.
Human mutation - 1 Feb 2013
Knauer Shirley K, Unruhe Britta, Karczewski Sarah, Hecht Rouven, Fetz Verena, Bier Carolin, Friedl Sandra, Wollenberg Barbara, Pries Ralph, Habtemichael Negusse, Heinrich Ulf-Rüdiger, Stauber Roland H
Abstract excerpt
Survivin (BIRC5) is an acknowledged cancer therapy-resistance factor and overexpressed in head and neck squamous cell carcinomas (HNSCC). Driven by its nuclear export signal (NES), Survivin shuttles between the nucleus and the cytoplasm, and is detectable in both cellular compartments in tumor biopsies. Although predominantly nuclear Survivin is considered a favorable prognostic disease marker for HNSCC patients,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.